E. Yoshida's Profile

Role	Title	Level	Year	L/R
🐜	Telaprevir for previously untreated chronic hepatitis C virus infection. 24 auth. I. Jacobson, J. Mchutchison, G. Dusheiko, A. Bisceglie, K. Reddy, N. Bzowej, P. Marcellin, A. Muir, P. Ferenci, R. Flisiak, ... J. George, M. Rizzetto, D. Shouval, R. Solá, R. Terg, E. Yoshida, N. Adda, L. Bengtsson, A. Sankoh, Tara L. Kieffer, S. George, R. Kauffman, S. Zeuzem, V. Phar	11	2011	11 🐜
🐜	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. 24 auth. J. Feld, I. Jacobson, C. Hézode, T. Asselah, P. Ruane, N. Gruener, A. Abergel, A. Mangia, Ching‐lung Lai, H. L. Chan, ... F. Mazzotta, Christophe Moreno, E. Yoshida, S. Shafran, W. Towner, T. Tran, J. McNally, A. Osinusi, E. Svarovskaia, Yanni Zhu, D. Brainard, J. Mchutchison, K. Agarwal, S. Zeuzem	10	2015	10 🐜
🐜	ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. 17 auth. F. Poordad, C. Hézode, R. Trinh, K. Kowdley, S. Zeuzem, K. Agarwal, M. Shiffman, H. Wedemeyer, T. Berg, E. Yoshida, ... X. Forns, Sandra S. Lovell, Barbara Da Silva-Tillmann, Christine A. Collins, A. Campbell, T. Podsadecki, B. Bernstein	9	2014	9 🐜
🐜	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. 25 auth. M. Manns, D. Samuel, E. Gane, D. Mutimer, G. McCaughan, M. Buti, M. Prieto, J. Calleja, M. Peck‐Radosavljevic, B. Müllhaupt, K. Agarwal, P. Angus, E. Yoshida, M. Colombo, M. Rizzetto, ... H. Dvory‐Sobol, J. Denning, S. Arterburn, P. Pang, D. Brainard, J. Mchutchison, J. Dufour, H. Van Vlierberghe, B. van Hoek, X. Forns	8	2016	8 🐜
🐜	Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants 9 auth. R. Perrillo, E. Schiff, E. Yoshida, A. Statler, K. Hirsch, T. Wright, ... K. Gutfreund, P. Lamy, A. Murray	8	2000	8 🐜
🐜	Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment 17 auth. E. Gane, E. Lawitz, D. Pugatch, G. Papatheodoridis, N. Bräu, A. Brown, S. Pol, V. Leroy, M. Persico, Christophe Moreno, ... M. Colombo, E. Yoshida, D. Nelson, Christine A. Collins, Y. Lei, M. Kosloski, F. Mensa	8	2017	8 🐜
🐜	Analysis of causes of death in liver transplant recipients who survived more than 3 years 8 auth. Jatinder S. Pruthi, Katherine Medkiff, K. Esrason, J. Donovan, E. Yoshida, S. Erb, ... U. Steinbrecher, T. Fong	8	2001	8 🐜
🐬	Choledochal cysts: part 1 of 3: classification and pathogenesis. J. Singham, E. Yoshida, C. Scudamore	7	2009	7 🐬
🐜	An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa‐2b combination therapy for chronic hepatitis C 9 auth. K. Patel, Y. Benhamou, E. Yoshida, K. Kaita, S. Zeuzem, M. Torbenson, ... E. Pulkstenis, G. Subramanian, J. Mchutchison	7	2009	7 🐜
🐬	Interferon‐Based Combination Anti‐Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative Analysis C. S. Wang, H. Ko, E. Yoshida, C. Marra, K. Richardson	7	2006	7 🐬
🐜	Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2) 20 auth. E. Lawitz, G. Matusow, E. Dejesus, E. Yoshida, F. Felizarta, R. Ghalib, E. Godofsky, R. Herring, G. Poleynard, A. Sheikh, ... H. Tobias, M. Kugelmas, R. Kalmeijer, M. Peeters, O. Lenz, B. Fevery, G. De La Rosa, Jane Scott, R. Sinha, J. Witek	7	2016	7 🐜
🦁	Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus 18 auth. E. Yoshida, M. Sulkowski, E. Gane, R. Herring, V. Ratziu, Xiao Ding, Jing Wang, S. Chuang, Julie Ma, J. McNally, ... L. Stamm, D. Brainard, W. Symonds, J. Mchutchison, K. Beavers, I. Jacobson, K. Reddy, E. Lawitz	7	2015	7 🦁